Results 151 to 160 of about 6,174 (184)

3075 Guillain-Barré syndrome following treatment with binimetinib and encorafenib for metastatic melanoma

BMJ Neurology Open
Michael Hayes, Andrew Swayne, Donald Craig, Cullen O'Gorman   +3 more
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Encorafenib and Binimetinib

2021
The BRAF/MEK inhibitors, encorafenib and binimetinib, is the FDA/EMA-approved combination used in BRAF-positive melanoma. The phase III study showed an improvement in progression-free survival (PFS) and overall survival (OS) with good tolerability. A direct comparison of monotherapy showed better results in the arm with encorafenib over vemurafenib ...
Iwona Lugowska, Paweł Rogala
openaire   +1 more source

Binimetinib/encorafenib

Reactions Weekly, 2022
  +5 more sources

Binimetinib

Reactions Weekly, 2021
openaire   +1 more source

Binimetinib/Encorafenib

Reactions Weekly
  +7 more sources

Binimetinib/encorafenib

Reactions Weekly, 2021
  +4 more sources

Binimetinib

Reactions Weekly, 2022
openaire   +1 more source

Binimetinib/encorafenib

Reactions Weekly, 2023
  +4 more sources